FIELD: medicine; pharmaceuticals.
SUBSTANCE: present invention relates to immunology. Disclosed is a chimeric antigenic receptor (CAR) containing an antigen-binding domain specific for thymic stromal lymphopoietin receptor (TSLPR), a transmembrane domain and an intracellular domain of T-cell signaling. Also disclosed is a CAR coding nucleic acid, a vector, a host cell, a cell population, a pharmaceutical composition, a method for detecting cancer, methods of treating or preventing cancer and proliferative disorder and a method for determining whether a subject with a proliferative disease is a candidate for treating the aforesaid CAR.
EFFECT: present invention can find further application in adoptive therapy of various diseases associated with a mutation in the IKZF gene and characterized by high expression of TSLPR, such as acute lymphoblastic leukemia (ALL).
30 cl, 26 dwg, 3 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CHIMERIC ANTIGEN RECEPTORS M971 | 2018 |
|
RU2770411C1 |
| M971 CHIMERIC ANTIGEN RECEPTORS | 2013 |
|
RU2658485C2 |
| CHIMERIC ANTIGENIC RECEPTORS TO CD22 | 2012 |
|
RU2644243C2 |
| CHIMERIC ANTIGEN RECEPTORS TARGETING B-CELL MATURATION ANTIGEN | 2013 |
|
RU2650805C2 |
| CHIMERIC ANTIGEN RECEPTORS TARGETED B-CELL MATURATION ANTIGEN | 2013 |
|
RU2766608C2 |
| MODIFIED MONOCYTES/MACROPHAGES EXPRESSING CHIMERIC ANTIGEN RECEPTORS AND THEIR APPLICATIONS | 2016 |
|
RU2766690C2 |
| GLYCAN-DEPENDENT IMMUNOTHERAPY MOLECULES | 2016 |
|
RU2754661C2 |
| TREATING CANCER BY HUMANISED ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR | 2014 |
|
RU2711975C2 |
| CANCER TREATMENT USING CHIMERIC ANTIGEN-SPECIFIC RECEPTOR BASED ON HUMANISED ANTI-EGFRvIII ANTIBODY | 2014 |
|
RU2708032C2 |
| TRANSPOSASE POLYPEPTIDES AND USE THEREOF | 2016 |
|
RU2735700C2 |
